Drug Profile
Brimonidine/dorzolamide/timolol - Laboratorios Sophia
Alternative Names: Krytantek PF; PRO-122Latest Information Update: 13 Jan 2021
Price :
$50
*
At a glance
- Originator Laboratorios Sophia
- Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Quinoxalines; Small molecules; Sulfonamides; Thiadiazoles; Thiophenes
- Mechanism of Action Alpha 2 adrenergic receptor agonists; Beta-adrenergic receptor antagonists; Carbonic anhydrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Ocular hypertension
Most Recent Events
- 12 Jan 2021 Laboratorios Sophia plans a phase IV trial for Ocular hypertension in patients with open-angle glaucoma (Opthalmic, preservative free solution) in May 2021 (NCT04702789)
- 22 Oct 2020 Phase III PRO-122LATAM trial is still ongoing for Ocular hypertension in Mexico (NCT03193333)
- 08 Nov 2018 Chemical structure information added